Similar articles

• Secondary medical prevention among Danish patients hospitalised with either peripheral arterial disease or myocardial infarction.

  Gasse C, Jacobsen J, Larsen AC, Schmidt EB, Johannesen NL, Videbaek J, Sørensen HT, Johnsen SP. Gasse C, et al. Eur J Vasc Endovasc Surg. 2008 Jan;35(1):51-8. doi: 10.1016/j.ejvs.2007.08.008. Epub 2007 Oct 17. Eur J Vasc Endovasc Surg. 2008. PMID: 17923426
• Pharmacological treatment after acute myocardial infarction from 2001 to 2006: a survey in Italian primary care.

  Filippi A, D'Ambrosio G, Giustini SE, Pecchioli S, Mazzaglia G, Cricelli C. Filippi A, et al. J Cardiovasc Med (Hagerstown). 2009 Sep;10(9):714-8. doi: 10.2459/JCM.0b013e32832c6110. J Cardiovasc Med (Hagerstown). 2009. PMID: 19465867
• Intermittent claudication: a plea for guidelines for medical management.

  Powell JT. Powell JT. Eur J Vasc Endovasc Surg. 2007 Apr;33(4):451-2. doi: 10.1016/j.ejvs.2006.11.014. Epub 2006 Dec 29. Eur J Vasc Endovasc Surg. 2007. PMID: 17196850 No abstract available.
• Optimal medical management of peripheral arterial disease.

  Rice TW, Lumsden AB. Rice TW, et al. Vasc Endovascular Surg. 2006 Aug-Sep;40(4):312-27. doi: 10.1177/1538574406291835. Vasc Endovascular Surg. 2006. PMID: 16959725 Review.
• The use of secondary medical prevention after primary vascular reconstruction: studies on usage and effectiveness.

  Høgh AL. Høgh AL. Dan Med J. 2012 Sep;59(9):B4514. Dan Med J. 2012. PMID: 22951205 Review.